Edition:
United Kingdom

People: Chr Hansen Holding A/S (CHRH.CO)

CHRH.CO on Copenhagen Stock Exchange

546.80DKK
21 Aug 2019
Change (% chg)

-- (--)
Prev Close
kr.546.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
248,247
52-wk High
kr.758.00
52-wk Low
kr.529.60

Schaefer, Thomas 

Mr. Thomas Schaefer has been Executive Vice President, Chief Scientific Officer, Research & Development and Member of the Executive Board at Chr. Hansen Holding A/S since November 1, 2017. He holds Ph.D. in Microbiology from Freie Universitaet Berlin, Germany. He has 23 years of experience from Novozymes. As a German national, Thomas Schaefer’s professional career started in 1994 where he joined the enzyme division of Novo Nordisk (in 2000 split into Novozymes) in Microbial Screening as a PostDoc. Throughout his years in Novozymes, he has held various senior positions primarily within R&D and Business Development. In 2013 Thomas Schaefer played a key role in making the BioAg Alliance with Monsanto a reality. This led to three years of expatriation in North Carolina, US, where he established Novozymes’ BioAg Application Research unit in RTP. Thomas Schaefer’s experience spans across both bacteria and enzymes under the umbrella of which he is further the co-inventor on a number of patents as well as publisher of several scientific papers and publications with WWF, WEF and the German Bioeconomy council. He is Member of the Board of the BioInnovation Institute and the Advisory Board for DTU Bioengineering.

Basic Compensation

Total Annual Compensation, EUR 280,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR 30,000
All Other, EUR --
Fiscal Year Total, EUR 310,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --